Scott H Maurer1, Pamela S Hinds2, Bryce B Reeve3, Jennifer W Mack4, Molly McFatrich3, Li Lin3, Janice S Withycombe5, Shana S Jacobs2, Justin N Baker6, Sharon M Castellino7, David R Freyer8,9. 1. UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. Children's National Health System, Washington, DC. 3. Duke University School of Medicine, Durham, North Carolina. 4. Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts. 5. Clemson University School of Nursing, Clemson, South Carolina. 6. St. Jude Children's Research Hospital, Memphis, Tennessee. 7. Children's Healthcare of Atlanta, Atlanta, Georgia. 8. Children's Hospital Los Angeles, Los Angeles, California. 9. Keck School of Medicine, University of Southern California, Los Angeles, California.
Abstract
BACKGROUND: The Lansky Play-Performance Scale (LPPS) is often used to determine a child's performance status for cancer clinical trial eligibility. Differences between clinician and caregiver LPPS ratings and their associations with child-reported functioning have not been evaluated. METHODS: Children aged 7 to 18 years who were receiving cancer treatment and their caregivers were recruited from 9 pediatric cancer centers. Caregivers and clinicians reported LPPS scores, and children completed Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric functioning and symptom measures before treatment (time 1 [T1]) and after treatment (time 2 [T2]). t tests and mixed-linear models were used to assess differences in caregiver and clinician LPPS scores; polyserial correlations quantified associations between PROMIS and LPPS scores. RESULTS: Of 482 children, 281 had matched caregiver- and clinician-reported LPPS T1/T2 scores. Caregivers rated children significantly worse on the LPPS than clinicians at both T1 (mean, 73.3 vs 87.4; P < .01) and T2 (mean, 67.9 vs 83.1; P < .01). These differences were not related to a child's age (P = .89), diagnosis (P = .17), or sex (P = .64) or to the time point (P = .45). Small to moderate associations existed between caregiver- and clinician-reported LPPS ratings and child-reported PROMIS scores for mobility (caregiver T1/T2 r = 0.51/0.45; P < .01; clinician T1/T2 r = 0.40/0.35; P < .01), fatigue (caregiver T1/T2 r = -0.46/-0.37; P < .01; clinician T1/T2 r = -0.26/-0.27; P < .01), and pain interference (caregiver T1/T2 r = -0.32/-0.30; P < .01; clinician T1/T2 r = -0.17/-0.31; P < .01). Caregivers and clinicians assigned significantly lower LPPS scores at T2 (caregiver Δ = -5.37; P < .01; clinician Δ = -4.20; P < .01), whereas child-reported PROMIS scores were clinically stable. CONCLUSIONS: Significant differences between clinician and caregiver LPPS ratings of child performance were sustained over time; their associations with child reports were predominantly small to moderate. These data suggest that clinician-reported LPPS ratings by themselves are inadequate for determining clinical trial eligibility and should be supplemented by appropriate measures of a child's functional status reflecting the child and caregiver perspectives.
BACKGROUND: The Lansky Play-Performance Scale (LPPS) is often used to determine a child's performance status for cancer clinical trial eligibility. Differences between clinician and caregiver LPPS ratings and their associations with child-reported functioning have not been evaluated. METHODS: Children aged 7 to 18 years who were receiving cancer treatment and their caregivers were recruited from 9 pediatric cancer centers. Caregivers and clinicians reported LPPS scores, and children completed Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric functioning and symptom measures before treatment (time 1 [T1]) and after treatment (time 2 [T2]). t tests and mixed-linear models were used to assess differences in caregiver and clinician LPPS scores; polyserial correlations quantified associations between PROMIS and LPPS scores. RESULTS: Of 482 children, 281 had matched caregiver- and clinician-reported LPPS T1/T2 scores. Caregivers rated children significantly worse on the LPPS than clinicians at both T1 (mean, 73.3 vs 87.4; P < .01) and T2 (mean, 67.9 vs 83.1; P < .01). These differences were not related to a child's age (P = .89), diagnosis (P = .17), or sex (P = .64) or to the time point (P = .45). Small to moderate associations existed between caregiver- and clinician-reported LPPS ratings and child-reported PROMIS scores for mobility (caregiver T1/T2 r = 0.51/0.45; P < .01; clinician T1/T2 r = 0.40/0.35; P < .01), fatigue (caregiver T1/T2 r = -0.46/-0.37; P < .01; clinician T1/T2 r = -0.26/-0.27; P < .01), and pain interference (caregiver T1/T2 r = -0.32/-0.30; P < .01; clinician T1/T2 r = -0.17/-0.31; P < .01). Caregivers and clinicians assigned significantly lower LPPS scores at T2 (caregiver Δ = -5.37; P < .01; clinician Δ = -4.20; P < .01), whereas child-reported PROMIS scores were clinically stable. CONCLUSIONS: Significant differences between clinician and caregiver LPPS ratings of child performance were sustained over time; their associations with child reports were predominantly small to moderate. These data suggest that clinician-reported LPPS ratings by themselves are inadequate for determining clinical trial eligibility and should be supplemented by appropriate measures of a child's functional status reflecting the child and caregiver perspectives.
Authors: Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Anuradha Banerjee; Roger J Packer; Lindsay B Kilburn; Stewart Goldman; Ian F Pollack; Ibrahim Qaddoumi; Regina I Jakacki; Paul G Fisher; Girish Dhall; Patricia Baxter; Susan G Kreissman; Clinton F Stewart; David T W Jones; Stefan M Pfister; Gilbert Vezina; Jessica S Stern; Ashok Panigrahy; Zoltan Patay; Benita Tamrazi; Jeremy Y Jones; Sofia S Haque; David S Enterline; Soonmee Cha; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi Journal: Lancet Oncol Date: 2019-05-28 Impact factor: 41.316
Authors: Debra E Irwin; Brian Stucky; Michelle M Langer; David Thissen; Esi Morgan Dewitt; Jin-Shei Lai; James W Varni; Karin Yeatts; Darren A DeWalt Journal: Qual Life Res Date: 2010-03-07 Impact factor: 4.147
Authors: Esi Morgan DeWitt; Brian D Stucky; David Thissen; Debra E Irwin; Michelle Langer; James W Varni; Jin-Shei Lai; Karin B Yeatts; Darren A Dewalt Journal: J Clin Epidemiol Date: 2011-02-02 Impact factor: 6.437
Authors: Birgit Geoerger; Hyoung Jin Kang; Michal Yalon-Oren; Lynley V Marshall; Catherine Vezina; Alberto Pappo; Theodore W Laetsch; Antonio S Petrilli; Martin Ebinger; Jacek Toporski; Julia Glade-Bender; Wayne Nicholls; Elizabeth Fox; Steven G DuBois; Margaret E Macy; Susan L Cohn; Kumudu Pathiraja; Scott J Diede; Scot Ebbinghaus; Navin Pinto Journal: Lancet Oncol Date: 2019-12-04 Impact factor: 41.316
Authors: David Thissen; Yang Liu; Brooke Magnus; Hally Quinn; Debbie S Gipson; Carlton Dampier; I-Chan Huang; Pamela S Hinds; David T Selewski; Bryce B Reeve; Heather E Gross; Darren A DeWalt Journal: Qual Life Res Date: 2015-06-29 Impact factor: 4.147
Authors: Sasja A Schepers; Simone M Sint Nicolaas; Heleen Maurice-Stam; Lotte Haverman; Chris M Verhaak; Martha A Grootenhuis Journal: Cancer Date: 2017-09-13 Impact factor: 6.860
Authors: Donna S Zhukovsky; Cathy L Rozmus; Rhonda S Robert; Eduardo Bruera; Robert J Wells; Gary B Chisholm; Julio A Allo; Marlene Z Cohen Journal: Cancer Date: 2015-07-28 Impact factor: 6.860
Authors: Giles W Robinson; Vasilisa A Rudneva; Ivo Buchhalter; Catherine A Billups; Sebastian M Waszak; Kyle S Smith; Daniel C Bowers; Anne Bendel; Paul G Fisher; Sonia Partap; John R Crawford; Tim Hassall; Daniel J Indelicato; Frederick Boop; Paul Klimo; Noah D Sabin; Zoltan Patay; Thomas E Merchant; Clinton F Stewart; Brent A Orr; Jan O Korbel; David T W Jones; Tanvi Sharma; Peter Lichter; Marcel Kool; Andrey Korshunov; Stefan M Pfister; Richard J Gilbertson; Robert P Sanders; Arzu Onar-Thomas; David W Ellison; Amar Gajjar; Paul A Northcott Journal: Lancet Oncol Date: 2018-05-16 Impact factor: 41.316
Authors: Bryce B Reeve; Molly McFatrich; Jennifer W Mack; Laura C Pinheiro; Shana S Jacobs; Justin N Baker; Janice S Withycombe; Li Lin; Courtney M Mann; Katie R Villabroza; Pamela S Hinds Journal: Pediatr Blood Cancer Date: 2020-01-06 Impact factor: 3.167
Authors: David R Freyer; Li Lin; Jennifer W Mack; Scott H Maurer; Molly McFatrich; Justin N Baker; Shana S Jacobs; Nicole Lucas; Janice S Withycombe; Deborah Tomlinson; Katie Rose Villabroza; Mia K Waldron; Pamela S Hinds; Bryce B Reeve Journal: J Clin Oncol Date: 2022-03-16 Impact factor: 50.717
Authors: Christopher B Forrest; Julia Schuchard; Cortney Bruno; Sandra Amaral; Elizabeth D Cox; Kathryn E Flynn; Pamela S Hinds; I-Chan Huang; Michael D Kappelman; Jerry A Krishnan; Rajesh B Kumar; Jin-Shei Lai; Amy S Paller; Wanda Phipatanakul; Laura E Schanberg; Kaharu Sumino; Elissa R Weitzman; Bryce B Reeve Journal: J Pediatr Date: 2022-03-02 Impact factor: 6.314
Authors: Janice S Withycombe; Molly McFatrich; Pamela S Hinds; Antonia Bennett; Li Lin; Scott H Maurer; Nicole R Lucas; Courtney M Mann; Sharon M Castellino; Justin N Baker; Bryce B Reeve Journal: Cancer Nurs Date: 2022-02-05 Impact factor: 2.760
Authors: Meaghann S Weaver; Shana S Jacobs; Janice S Withycombe; Jichuan Wang; Katie A Greenzang; Justin N Baker; Pamela S Hinds Journal: JAMA Netw Open Date: 2022-03-01
Authors: David Riedl; Thomas Licht; Alain Nickels; Maria Rothmund; Gerhard Rumpold; Bernhard Holzner; Vincent Grote; Michael J Fischer; Gustav Fischmeister Journal: Cancers (Basel) Date: 2022-10-04 Impact factor: 6.575